Age-related macular degeneration is an eye disease that can blur your central vision. It happens when aging causes damage to the macula — the part of the eye that controls sharp, straight-ahead vision. (Symbolic photo)
Keystone / Martin Ruetschi
An appeals court in France has overturned a record fine imposed by the French competition authority against the Swiss pharmaceutical companies Novartis and Roche.
This content was published on
2 minutes
Keystone-SDA/SWI/ug
Español
es
Se levantan las multas millonarias a los gigantes farmacéuticos
The verdict was announced by a court in Paris on Thursday.
Both firms were given a fine totaling €444 million (CHF438.9 million) in 2020 for following allegedly abusive practices, notably in the sale of the eye disease drug Lucentis at the expense of the Avastin drug treatment, which is up to 30 times cheaper.
Novartis was accused of conducting a communication campaign from 2008 to 2013 to discredit the use of Avastin in ophthalmology. The company was therefore fined the highest amount, €385 million, while Roche and its US subsidiary Genentech were fined €59 million.
In a first reaction, Novartis and Roche said they were “pleased” with the decision. They have denied allegations from the outset, arguing they acted appropriately in accordance with competition law and in the interests of patients at all times, according to the Swiss AWP news agency.
Different conclusion
The Paris court ruled that Avastin should be considered as no longer on the market from the time new legislation for the treatment of age-related macular degeneration came into effect in 2011.
The judges found that Novartis’ communications during the period under review were “moderate in tone”. They also found that the two companies’ communications had not been “alarmist or even misleading”.
Finally, the court held that the blocking behaviour of Roche, which had refused to provide Avastin samples requested by the health authorities for the launch of a scientific study, could not have had anti-competitive effects.
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
Geneva-based UN migration office cuts fifth of workforce
This content was published on
The UN's International Organisation for Migration HQ in Geneva is slashing 20% of its 1,000 staff due to the US aid freeze.
Switzerland budgets CHF 666m to rejoin EU research programmes
This content was published on
Rejoining European Union research programmes, such as Horizon Europe, will cost Switzerland an initial sum of CHF666 million.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss pharma industry fights lower drug prices in the US
This content was published on
A proposed US law aims to lower prescription drug prices. But Big Pharma is pulling out all the stops to lobby against it.
Swiss pharma giants fined by France in ongoing eye drug clash
This content was published on
Novartis and Roche have been fined by the French competition authority for applying abusive practices to push a costly eye injection drug.
High-priced medicine could be our best chance to lower drug prices
This content was published on
The best opportunity to rein in skyrocketing drug prices is coming from the most unlikely place – the highest priced therapies in the world.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.